Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Case report

Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature

Authors: David A Barr, Pravistadevi K Ramdial

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

The development of jaundice after initiation of HAART in HIV-TB co-infected patients is a challenging presentation in resource constrained settings, and is often attributed to drug induced liver injury (DILI).Some investigators have described hepatic tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) as a cause of liver disease in patients initiating HAART, which could also cause jaundice.

Case presentations

We report the clinical and histopathological features of five HIV-TB co-infected patients presenting with a syndrome of jaundice, tender hepatomegaly, bile canalicular enzyme rise and return of constitutional symptoms within 8 weeks of initiation of highly active antiretroviral therapy (HAART) for advanced HIV infection at a rural clinic in KwaZulu Natal, South Africa.
All five patients had been diagnosed with tuberculosis infection prior to HAART initiation and were on antituberculous medication at time of developing jaundice. There was evidence of multiple aetiologies of liver injury in all patients. However, based on clinical course and pathological findings, predominant hepatic injury was thought to be drug induced in one case and hepatic tuberculosis associated immune reconstitution inflammatory syndrome (TB-IRIS) in the other four.
In these later 4 patients, liver biopsy findings included necrotising and non-necrotising granulomatous inflammation in the lobules and portal tracts. The granulomas demonstrated – in addition to epithelioid histiocytes and Langhans giant cells – neutrophils, plasma cells and large numbers of lymphocytes, which are not features of a conventional untreated tuberculous response.

Conclusion

In this high TB prevalent, low resource setting, TB-IRIS may be an important cause of jaundice post-HAART initiation. Clinicopathological correlation is essential for optimal diagnosis. Further multi-organ based histopathological studies in the context of immune reconstitution would be useful to clinicians in low resource settings dealing with this challenging presentation.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO, UNAIDS, UNICEF: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. 2010, Geneva: World Health Organisation WHO, UNAIDS, UNICEF: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. 2010, Geneva: World Health Organisation
2.
go back to reference National Department of Health South Africa: The South African national tuberculosis control program practical guidelines. 2004, Pretoria: Republic of South Africa Department of Health National Department of Health South Africa: The South African national tuberculosis control program practical guidelines. 2004, Pretoria: Republic of South Africa Department of Health
3.
go back to reference National Department of Health South Africa: Clinical guidelines for the management of HIV & AIDS in adults and adolescents. 2010, Pretoria: National Department of Health South Africa National Department of Health South Africa: Clinical guidelines for the management of HIV & AIDS in adults and adolescents. 2010, Pretoria: National Department of Health South Africa
4.
go back to reference Cappell MS: Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am J Gastroenterol. 1991, 86: 1-15.PubMed Cappell MS: Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am J Gastroenterol. 1991, 86: 1-15.PubMed
5.
go back to reference Schneiderman DJ: Hepatobiliary abnormalities of AIDS. Gastroenterol Clin North Am. 1988, 17: 615-630.PubMed Schneiderman DJ: Hepatobiliary abnormalities of AIDS. Gastroenterol Clin North Am. 1988, 17: 615-630.PubMed
6.
go back to reference Pereira GH, Yamagutti DC, Mendonca JS: Evaluation of the histopathological hepatic lesions and opportunistic agents in Brazilian HIV patients. Rev Soc Bras Med Trop. 2010, 43: 1-3. 10.1590/S0037-86822010000100001.CrossRefPubMed Pereira GH, Yamagutti DC, Mendonca JS: Evaluation of the histopathological hepatic lesions and opportunistic agents in Brazilian HIV patients. Rev Soc Bras Med Trop. 2010, 43: 1-3. 10.1590/S0037-86822010000100001.CrossRefPubMed
7.
go back to reference Poles MA, Dieterich DT, Schwarz ED, Weinshel EH, Lew EA, Lew R, Scholes JV: Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol. 1996, 11: 170-177. 10.1097/00042560-199602010-00008.CrossRefPubMed Poles MA, Dieterich DT, Schwarz ED, Weinshel EH, Lew EA, Lew R, Scholes JV: Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol. 1996, 11: 170-177. 10.1097/00042560-199602010-00008.CrossRefPubMed
8.
go back to reference Cavicchi M, Pialoux G, Carnot F, Offredo C, Romana C, Deslandes P, Dupont B, Berthelot P, Pol S: Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase. Clin Infect Dis. 1995, 20: 606-610. 10.1093/clinids/20.3.606.CrossRefPubMed Cavicchi M, Pialoux G, Carnot F, Offredo C, Romana C, Deslandes P, Dupont B, Berthelot P, Pol S: Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase. Clin Infect Dis. 1995, 20: 606-610. 10.1093/clinids/20.3.606.CrossRefPubMed
9.
go back to reference Echejoh GO, Mandong BM, Tanko MN, Manasseh AN, Okeke EN, Agaba EI: Hepatic histopathological findings in HIV patients at postmortem in Jos university teaching hospital, Nigeria. Trop Doct. 2006, 36: 228-231. 10.1258/004947506778604832.CrossRefPubMed Echejoh GO, Mandong BM, Tanko MN, Manasseh AN, Okeke EN, Agaba EI: Hepatic histopathological findings in HIV patients at postmortem in Jos university teaching hospital, Nigeria. Trop Doct. 2006, 36: 228-231. 10.1258/004947506778604832.CrossRefPubMed
10.
go back to reference Viriyavejakul P, Rojanasunan P, Viriyavejakul A, Punyarit P, Punpoowong B, Khachansaksumet V, Riganti M, Pongponratn E: Opportunistic infections in the liver of HIV-infected patients in Thailand: a necropsy study. Southeast Asian J Trop Med Public Health. 2000, 31: 663-667.PubMed Viriyavejakul P, Rojanasunan P, Viriyavejakul A, Punyarit P, Punpoowong B, Khachansaksumet V, Riganti M, Pongponratn E: Opportunistic infections in the liver of HIV-infected patients in Thailand: a necropsy study. Southeast Asian J Trop Med Public Health. 2000, 31: 663-667.PubMed
11.
go back to reference Chalasani N, Wilcox CM: Etiology, evaluation, and outcome of jaundice in patients with acquired immunodeficiency syndrome. Hepatology. 1996, 23: 728-733. 10.1002/hep.510230412.CrossRefPubMed Chalasani N, Wilcox CM: Etiology, evaluation, and outcome of jaundice in patients with acquired immunodeficiency syndrome. Hepatology. 1996, 23: 728-733. 10.1002/hep.510230412.CrossRefPubMed
12.
go back to reference Akhtar AJ, Shaheen M: Jaundice in African-American and Hispanic patients with AIDS. J Natl Med Assoc. 2007, 99: 1381-1385.PubMedPubMedCentral Akhtar AJ, Shaheen M: Jaundice in African-American and Hispanic patients with AIDS. J Natl Med Assoc. 2007, 99: 1381-1385.PubMedPubMedCentral
13.
go back to reference Ocama P, Katwere M, Piloya T, Feld J, Opio KC, Kambugu A, Katabira E, Thomas D, Colebunders R, Ronald A: The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci. 2008, 8: 8-12.PubMedPubMedCentral Ocama P, Katwere M, Piloya T, Feld J, Opio KC, Kambugu A, Katabira E, Thomas D, Colebunders R, Ronald A: The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci. 2008, 8: 8-12.PubMedPubMedCentral
14.
go back to reference Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of liver disease in patients with HIV infection. Lancet. 2011, 377: 1198-1209. 10.1016/S0140-6736(10)62001-6.CrossRefPubMed Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of liver disease in patients with HIV infection. Lancet. 2011, 377: 1198-1209. 10.1016/S0140-6736(10)62001-6.CrossRefPubMed
15.
go back to reference Nunez M: Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010, 52: 1143-1155. 10.1002/hep.23716.CrossRefPubMed Nunez M: Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010, 52: 1143-1155. 10.1002/hep.23716.CrossRefPubMed
16.
go back to reference Nunez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006, 44: S132-S139.CrossRefPubMed Nunez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006, 44: S132-S139.CrossRefPubMed
17.
go back to reference Inductivo-Yu I, Bonacini M: Highly active antiretroviral therapy-induced liver injury. Curr Drug Saf. 2008, 3: 4-13. 10.2174/157488608783333916.CrossRefPubMed Inductivo-Yu I, Bonacini M: Highly active antiretroviral therapy-induced liver injury. Curr Drug Saf. 2008, 3: 4-13. 10.2174/157488608783333916.CrossRefPubMed
18.
go back to reference Sabin CA: Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis. 2004, 38 (Suppl 2): S56-S64.CrossRefPubMed Sabin CA: Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis. 2004, 38 (Suppl 2): S56-S64.CrossRefPubMed
20.
go back to reference Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001, 15: 1261-1268. 10.1097/00002030-200107060-00007.CrossRefPubMed Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001, 15: 1261-1268. 10.1097/00002030-200107060-00007.CrossRefPubMed
21.
go back to reference Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000, 283: 74-80. 10.1001/jama.283.1.74.CrossRefPubMed Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000, 283: 74-80. 10.1001/jama.283.1.74.CrossRefPubMed
22.
go back to reference den B M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van L R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000, 14: 2895-2902. 10.1097/00002030-200012220-00011.CrossRef den B M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van L R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000, 14: 2895-2902. 10.1097/00002030-200012220-00011.CrossRef
23.
go back to reference Saves M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le MV, Riviere C, Chene G, Leport C: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother. 2000, 44: 3451-3455. 10.1128/AAC.44.12.3451-3455.2000.CrossRefPubMedPubMedCentral Saves M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le MV, Riviere C, Chene G, Leport C: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother. 2000, 44: 3451-3455. 10.1128/AAC.44.12.3451-3455.2000.CrossRefPubMedPubMedCentral
24.
go back to reference Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001, 27: 426-431.CrossRefPubMed Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001, 27: 426-431.CrossRefPubMed
25.
go back to reference Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, Schlech WF, Katabira ET: Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci. 2011, 11: 16-23.PubMedPubMedCentral Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, Schlech WF, Katabira ET: Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci. 2011, 11: 16-23.PubMedPubMedCentral
26.
go back to reference Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A, Colebunders R, Thomas DL: Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010, 21: 553-557. 10.1258/ijsa.2010.010027.CrossRefPubMedPubMedCentral Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A, Colebunders R, Thomas DL: Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010, 21: 553-557. 10.1258/ijsa.2010.010027.CrossRefPubMedPubMedCentral
27.
go back to reference Meyssonnier V, Costagliola D, Caumes PE: Nevirapine-associated toxicity in Niger. HIV Med. 2008, 9: 62-63. 10.1111/j.1468-1293.2008.00516.x.CrossRefPubMed Meyssonnier V, Costagliola D, Caumes PE: Nevirapine-associated toxicity in Niger. HIV Med. 2008, 9: 62-63. 10.1111/j.1468-1293.2008.00516.x.CrossRefPubMed
28.
go back to reference Weidle PJ, Moore D, Mermin J, Buchacz K, Were W, Downing R, Kigozi A, Ndazima V, Peters P, Brooks JT: Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS. 2008, 22: 787-795. 10.1089/apc.2008.0020.CrossRefPubMed Weidle PJ, Moore D, Mermin J, Buchacz K, Were W, Downing R, Kigozi A, Ndazima V, Peters P, Brooks JT: Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS. 2008, 22: 787-795. 10.1089/apc.2008.0020.CrossRefPubMed
29.
go back to reference Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van CG: Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One. 2010, 5: e9183-10.1371/journal.pone.0009183.CrossRefPubMedPubMedCentral Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van CG: Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One. 2010, 5: e9183-10.1371/journal.pone.0009183.CrossRefPubMedPubMedCentral
30.
go back to reference Kim AA, Wanjiku L, Macharia DK, Wangai M, Isavwa A, Abdi H, Marston BJ, Ilako F, Kjaer M, Chebet K, De Cock KM, Weidle PJ: Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003–2005. J Int Assoc Physicians AIDS Care (Chic ). 2007, 6: 206-209. 10.1177/1545109707304494.CrossRef Kim AA, Wanjiku L, Macharia DK, Wangai M, Isavwa A, Abdi H, Marston BJ, Ilako F, Kjaer M, Chebet K, De Cock KM, Weidle PJ: Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003–2005. J Int Assoc Physicians AIDS Care (Chic ). 2007, 6: 206-209. 10.1177/1545109707304494.CrossRef
31.
go back to reference Hahn JA, Maier M, Byakika-Tusiime J, Oyugi JH, Bangsberg DR: Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda. J Int Assoc Physicians AIDS Care (Chic ). 2007, 6: 83-86. 10.1177/1545109707299356.CrossRef Hahn JA, Maier M, Byakika-Tusiime J, Oyugi JH, Bangsberg DR: Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda. J Int Assoc Physicians AIDS Care (Chic ). 2007, 6: 83-86. 10.1177/1545109707299356.CrossRef
32.
go back to reference Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, Gabillard D, Sorho S, Rouet F, Eholie S, Anglaret X: Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr. 2006, 42: 29-35. 10.1097/01.qai.0000219777.04927.50.CrossRefPubMed Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, Gabillard D, Sorho S, Rouet F, Eholie S, Anglaret X: Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr. 2006, 42: 29-35. 10.1097/01.qai.0000219777.04927.50.CrossRefPubMed
33.
go back to reference Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L: Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006, 20: 1163-1169. 10.1097/01.aids.0000226957.79847.d6.CrossRefPubMed Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L: Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006, 20: 1163-1169. 10.1097/01.aids.0000226957.79847.d6.CrossRefPubMed
34.
go back to reference Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E: Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011, 6: e27810-10.1371/journal.pone.0027810.CrossRefPubMedPubMedCentral Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E: Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011, 6: e27810-10.1371/journal.pone.0027810.CrossRefPubMedPubMedCentral
35.
go back to reference Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD: Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007, 21: 1301-1308. 10.1097/QAD.0b013e32814e6b08.CrossRefPubMed Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD: Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007, 21: 1301-1308. 10.1097/QAD.0b013e32814e6b08.CrossRefPubMed
36.
go back to reference Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, Abrams EJ, Dabis F, Ekouevi DK: Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. BMC Infect Dis. 2010, 10: 188-10.1186/1471-2334-10-188.CrossRefPubMedPubMedCentral Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, Abrams EJ, Dabis F, Ekouevi DK: Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. BMC Infect Dis. 2010, 10: 188-10.1186/1471-2334-10-188.CrossRefPubMedPubMedCentral
37.
go back to reference Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005, 191: 825-829. 10.1086/428093.CrossRefPubMed Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005, 191: 825-829. 10.1086/428093.CrossRefPubMed
38.
go back to reference Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ: Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007, 44: 456-462. 10.1097/QAI.0b013e318033ffa1.CrossRefPubMed Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ: Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007, 44: 456-462. 10.1097/QAI.0b013e318033ffa1.CrossRefPubMed
39.
go back to reference Zimmerman HJ: Agents employed in the treatment of infectious and parasitic diseases. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Edited by: Zimmerman HJ. 1978, New York: Appleton-Century-Crofts, 492-493. 1st Zimmerman HJ: Agents employed in the treatment of infectious and parasitic diseases. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Edited by: Zimmerman HJ. 1978, New York: Appleton-Century-Crofts, 492-493. 1st
40.
go back to reference Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR: Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975, 69: 289-302.PubMed Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR: Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975, 69: 289-302.PubMed
41.
go back to reference Gulliford M, Mackay AD, Prowse K: Cholestatic jaundice caused by ethambutol. Br Med J (Clin Res Ed). 1986, 292: 866-10.1136/bmj.292.6524.866.CrossRef Gulliford M, Mackay AD, Prowse K: Cholestatic jaundice caused by ethambutol. Br Med J (Clin Res Ed). 1986, 292: 866-10.1136/bmj.292.6524.866.CrossRef
43.
go back to reference Maria VA, Victorino RM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997, 26: 664-669. 10.1002/hep.510260319.CrossRefPubMed Maria VA, Victorino RM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997, 26: 664-669. 10.1002/hep.510260319.CrossRefPubMed
44.
go back to reference Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez DLC: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001, 33: 123-130. 10.1053/jhep.2001.20645.CrossRefPubMed Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez DLC: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001, 33: 123-130. 10.1053/jhep.2001.20645.CrossRefPubMed
45.
go back to reference Ramachandran R, Kakar S: Histological patterns in drug-induced liver disease. J Clin Pathol. 2009, 62: 481-492. 10.1136/jcp.2008.058248.CrossRefPubMed Ramachandran R, Kakar S: Histological patterns in drug-induced liver disease. J Clin Pathol. 2009, 62: 481-492. 10.1136/jcp.2008.058248.CrossRefPubMed
46.
go back to reference Ishak KG, Zimmerman HJ: Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am. 1995, 24: 759-786.PubMed Ishak KG, Zimmerman HJ: Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am. 1995, 24: 759-786.PubMed
47.
go back to reference Lewis JH, Kleiner DE: Hepatic injury due to drugs, chemicals and toxins. MacSween's Pathology of the Liver. Edited by: Burt AD, Portmann BC, Ferrell LD. 2007, Philadelphia, 649-759. 5th Lewis JH, Kleiner DE: Hepatic injury due to drugs, chemicals and toxins. MacSween's Pathology of the Liver. Edited by: Burt AD, Portmann BC, Ferrell LD. 2007, Philadelphia, 649-759. 5th
48.
go back to reference Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Ng'ang'a LW, Power C, Githui WA, Porter JD, Lucas SB: Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2000, 24: 23-29.CrossRefPubMed Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Ng'ang'a LW, Power C, Githui WA, Porter JD, Lucas SB: Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2000, 24: 23-29.CrossRefPubMed
49.
go back to reference Lawn SD, Wood R: Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS. 2007, 21: 2362-2363. 10.1097/QAD.0b013e3282f1be39.CrossRefPubMed Lawn SD, Wood R: Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS. 2007, 21: 2362-2363. 10.1097/QAD.0b013e3282f1be39.CrossRefPubMed
50.
go back to reference Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ, Wilkinson KA, Wilkinson RJ: Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis. 2009, 48: 667-676. 10.1086/596764.CrossRefPubMedPubMedCentral Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ, Wilkinson KA, Wilkinson RJ: Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis. 2009, 48: 667-676. 10.1086/596764.CrossRefPubMedPubMedCentral
51.
go back to reference Haddow LJ, Moosa MY, Easterbrook PJ: Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010, 24: 103-108. 10.1097/QAD.0b013e32832ec1f4.CrossRefPubMed Haddow LJ, Moosa MY, Easterbrook PJ: Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010, 24: 103-108. 10.1097/QAD.0b013e32832ec1f4.CrossRefPubMed
52.
go back to reference Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S, Miglani S, Gupta D: A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res. 2010, 131: 804-808.PubMed Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S, Miglani S, Gupta D: A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res. 2010, 131: 804-808.PubMed
53.
go back to reference Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R: Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008, 8: 516-523. 10.1016/S1473-3099(08)70184-1.CrossRefPubMedPubMedCentral Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R: Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008, 8: 516-523. 10.1016/S1473-3099(08)70184-1.CrossRefPubMedPubMedCentral
54.
go back to reference Haddow LJ, Sahid F, Moosa MY: Cryptococcal breast abscess in an HIV-positive patient: arguments for reviewing the definition of immune reconstitution inflammatory syndrome. J Infect. 2008, 57: 82-84. 10.1016/j.jinf.2008.01.010.CrossRefPubMed Haddow LJ, Sahid F, Moosa MY: Cryptococcal breast abscess in an HIV-positive patient: arguments for reviewing the definition of immune reconstitution inflammatory syndrome. J Infect. 2008, 57: 82-84. 10.1016/j.jinf.2008.01.010.CrossRefPubMed
55.
go back to reference Piratvisuth T, Siripaitoon P, Sriplug H, Ovartlarnporn B: Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus. J Gastroenterol Hepatol. 1999, 14: 146-149.CrossRefPubMed Piratvisuth T, Siripaitoon P, Sriplug H, Ovartlarnporn B: Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus. J Gastroenterol Hepatol. 1999, 14: 146-149.CrossRefPubMed
57.
58.
go back to reference Vavricka SR, Van MJ, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002, 36: 164-172.CrossRefPubMed Vavricka SR, Van MJ, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002, 36: 164-172.CrossRefPubMed
59.
go back to reference Heller T, Wallrauch C, Lessells RJ: Reply to Sharma et Al. and Saukkonen et Al. Clin Infect Dis. 2010, 51: 255-CrossRefPubMed Heller T, Wallrauch C, Lessells RJ: Reply to Sharma et Al. and Saukkonen et Al. Clin Infect Dis. 2010, 51: 255-CrossRefPubMed
Metadata
Title
Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature
Authors
David A Barr
Pravistadevi K Ramdial
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-257

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.